AU5640390A - Suramin type compounds and angiostatic steroids to inhibit angiogenesis - Google Patents

Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Info

Publication number
AU5640390A
AU5640390A AU56403/90A AU5640390A AU5640390A AU 5640390 A AU5640390 A AU 5640390A AU 56403/90 A AU56403/90 A AU 56403/90A AU 5640390 A AU5640390 A AU 5640390A AU 5640390 A AU5640390 A AU 5640390A
Authority
AU
Australia
Prior art keywords
suramin
type compounds
inhibit angiogenesis
angiostatic steroids
angiostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56403/90A
Inventor
Paul A. Aristoff
Mark A. Mitchell
John W. Wilks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AU5640390A publication Critical patent/AU5640390A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU56403/90A 1989-06-16 1990-05-17 Suramin type compounds and angiostatic steroids to inhibit angiogenesis Abandoned AU5640390A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36693589A 1989-06-16 1989-06-16
US366935 1989-06-16
US48304490A 1990-02-16 1990-02-16
US483044 1990-02-16

Publications (1)

Publication Number Publication Date
AU5640390A true AU5640390A (en) 1991-01-08

Family

ID=27003588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56403/90A Abandoned AU5640390A (en) 1989-06-16 1990-05-17 Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Country Status (4)

Country Link
EP (1) EP0477195A1 (en)
JP (1) JPH04506066A (en)
AU (1) AU5640390A (en)
WO (1) WO1990015816A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657690B2 (en) * 1990-06-11 1995-03-23 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
DK0614463T3 (en) * 1991-11-22 2003-03-31 Alcon Lab Inc Angiostatic steroids
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9225475D0 (en) * 1992-12-05 1993-01-27 Imp Cancer Res Tech Compounds to combat angiogenesis
ATE179712T1 (en) * 1993-03-01 1999-05-15 Glycan Pharm Inc ANALOGS FOR SPECIFIC OLIGOSACCHARIDE-PROTEIN INTERACTIONS AND THEIR USES
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
FR2736914B1 (en) * 1995-07-21 1997-08-22 Adir NOVEL AMINOPHENYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1276031B1 (en) * 1995-10-31 1997-10-24 Angelini Ricerche Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
CA2208916A1 (en) * 1997-07-03 1999-01-03 Hyal Pharmaceutical Corporation Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
EP1124545B1 (en) 1998-08-11 2004-12-15 EntreMed, Inc. Use of 2-methoxyestradiol as anti-fungal agents
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
BRPI0113042B8 (en) 2000-08-05 2021-05-25 Glaxo Group Ltd compound of the formula or a physiologically acceptable solvate thereof, use thereof, pharmaceutical composition, pharmaceutical formulation, method of treating a human or animal subject with an inflammatory and/or allergic condition, and, process for preparing a compound or a solvate thereof
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1603543A4 (en) * 2003-02-28 2009-03-04 Florey Howard Inst Therapeutic compositions
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc Antiangiogenic agents
IL169622A0 (en) * 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
WO2007109312A2 (en) 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP3656385A1 (en) 2008-05-28 2020-05-27 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
BR122020006408B1 (en) 2013-03-29 2021-09-28 The Johns Hopkins University UNIT DOSE OF COLONY-FORMING UNITS OF C. NOVYI, PHARMACEUTICAL COMPOSITION AND USE OF C. NOVYI NT TO TREAT OR MITIGATE AN EFFECT OF A SOLID TUMOR PRESENT IN A HUMAN BEING
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
CA3168216A1 (en) 2015-01-30 2016-08-04 Biomed Valley Discoveries, Inc. Crystalline c21h22cl2n4o2 malonate
EP3250562A4 (en) 2015-01-30 2018-07-11 Biomed Valley Discoveries, Inc. Crystalline forms of c21h22ci2n4o2
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3291815A (en) * 1958-12-05 1966-12-13 Pfizer & Co C 6-fluoro-16alpha-methyl corticosteroids
CH628355A5 (en) * 1976-02-24 1982-02-26 Ciba Geigy Ag METHOD FOR PRODUCING NEW ANDROSTADIEN-17BETA-CARBONIC ACIDS AND THEIR ESTERS AND SALTS.
CH634081A5 (en) * 1977-04-13 1983-01-14 Ciba Geigy Ag Process for the preparation of novel androstadiene-17beta-carboxylic acid esters
IT7967677A0 (en) * 1978-04-05 1979-03-30 Syntex Inc DERIVATIVES OF 4-HALOGEN ETHIAN ACID WITH ANTI-INFLAMMATORY ACTION AND PROCEDURE FOR THEIR PREPARATION
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657690B2 (en) * 1990-06-11 1995-03-23 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis

Also Published As

Publication number Publication date
WO1990015816A1 (en) 1990-12-27
JPH04506066A (en) 1992-10-22
EP0477195A1 (en) 1992-04-01

Similar Documents

Publication Publication Date Title
AU5640390A (en) Suramin type compounds and angiostatic steroids to inhibit angiogenesis
US5095037B1 (en) Combined anti-inflammatory agent
GB2218334B (en) Cyclosprorin compositions for topical application
EP0409383A3 (en) Estradiol compositions and methods for topical applications
HK125196A (en) Novel steroid derivatives
EP0502080A4 (en) Anti-inflammatory compositions and methods
AU5974390A (en) Topical spironolactone composition
AU655267B3 (en) Improvements in or relating to orthotic devices
AU3707989A (en) Angiogenesis inhibitor
GB2219798B (en) Anti-inflammatory 2-arylalkyl-pyridine derivatives
AU7656687A (en) Anti-inflammatory compositions
GB8821183D0 (en) Composition of matter
AU8124487A (en) Reactive organo-clay compounds and derivatives thereof
AU3626889A (en) Process for the preparation of alkyl glycosides
AU6007590A (en) Saccharide derivatives of protocatechualdehyde
GB2219797B (en) 'anti-inflammatory carbocyclic-fused pyridine derivatives'
GB8821186D0 (en) Compositions of matter
AU2355188A (en) Polycyclic compounds and pharmaceutical compositions thereof
IL91067A0 (en) Topical pharmaceutical compositions comprising certain steroids
GB8916636D0 (en) Steroid ethers
NZ223832A (en) Substituted hydroxynaphthalenes and anti-inflammatory and anti-psoriatic compositions
AU6461790A (en) Compositions of matter
GB8815822D0 (en) Steroid ethers
GB8802326D0 (en) Steroid derivatives
AU655159C (en) Improvements in or relating to orthotic devices